459 related articles for article (PubMed ID: 28477389)
1. Paradoxical ulcerative colitis during adalimumab treatment of psoriasis resolved by switch to ustekinumab.
Kolios AGA; Biedermann L; Weber A; Navarini AA; Meier J; Cozzio A; French LE
Br J Dermatol; 2018 Feb; 178(2):551-555. PubMed ID: 28477389
[TBL] [Abstract][Full Text] [Related]
2. Ustekinumab for the treatment of paradoxical skin reactions and cutaneous manifestations of inflammatory bowel diseases.
Wu J; Smogorzewski J
Dermatol Ther; 2021 May; 34(3):e14883. PubMed ID: 33594811
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry.
Zweegers J; Groenewoud JMM; van den Reek JMPA; Otero ME; van de Kerkhof PCM; Driessen RJB; van Lümig PPM; Njoo MD; Ossenkoppele PM; Mommers JM; Koetsier MIA; Arnold WP; Andriessen MPM; Kuijpers ALA; Berends MAM; Kievit W; de Jong EMGJ
Br J Dermatol; 2017 Apr; 176(4):1001-1009. PubMed ID: 27579864
[TBL] [Abstract][Full Text] [Related]
4. Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry.
Zweegers J; van den Reek JM; van de Kerkhof PC; Otero ME; Kuijpers AL; Koetsier MI; Arnold WP; Berends MA; Weppner-Parren L; Ossenkoppele PM; Njoo MD; Mommers JM; van Lümig PP; Driessen RJ; Kievit W; de Jong EM
Br J Dermatol; 2016 Aug; 175(2):340-7. PubMed ID: 26989852
[TBL] [Abstract][Full Text] [Related]
5. Biologic drug survival in Israeli psoriasis patients.
Shalom G; Cohen AD; Ziv M; Eran CB; Feldhamer I; Freud T; Berman E; Oren S; Hodak E; Pavlovsky L
J Am Acad Dermatol; 2017 Apr; 76(4):662-669.e1. PubMed ID: 28038888
[TBL] [Abstract][Full Text] [Related]
6. Development of hidradenitis suppurativa in a patient treated with ustekinumab for her psoriasis: A potential paradoxical reaction?
Gkini MA; Bewley AP
Dermatol Ther; 2018 Nov; 31(6):e12742. PubMed ID: 30221819
[No Abstract] [Full Text] [Related]
7. Etanercept, adalimumab, and ustekinumab in psoriasis: analysis of 209 treatment series in Austria.
Richter L; Vujic I; Sesti A; Monshi B; Sanlorenzo M; Posch C; Rappersberger K
J Dtsch Dermatol Ges; 2017 Mar; 15(3):309-317. PubMed ID: 28240404
[TBL] [Abstract][Full Text] [Related]
8. Thrombocytopenia in a psoriatic patient sequentially treated with adalimumab, secukinumab and ustekinumab.
Nakahara T; Konishi S; Yasukochi Y; Esaki H; Tsuji G; Kido-Nakahara M; Furue M
J Dermatol; 2019 May; 46(5):e157-e158. PubMed ID: 30353917
[No Abstract] [Full Text] [Related]
9. Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting.
Baniandrés O; Rodríguez-Soria VJ; Romero-Jiménez RM; Suárez R
Actas Dermosifiliogr; 2015 Sep; 106(7):569-77. PubMed ID: 25935194
[TBL] [Abstract][Full Text] [Related]
10. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study.
Fouache D; Goëb V; Massy-Guillemant N; Avenel G; Bacquet-Deschryver H; Kozyreff-Meurice M; Ménard JF; Muraine M; Savoye G; Le Loët X; Tharasse C; Vittecoq O
Rheumatology (Oxford); 2009 Jul; 48(7):761-4. PubMed ID: 19395543
[TBL] [Abstract][Full Text] [Related]
11. Observational case series on adalimumab-induced paradoxical hidradenitis suppurativa.
Delobeau M; Abdou A; Puzenat E; Deveza E; Biver-Dalle C; van de Laak A; Roche-Kubler B; Vuitton L; Koch S; Wendling D; Aubin F
J Dermatolog Treat; 2016; 27(3):251-3. PubMed ID: 26368546
[TBL] [Abstract][Full Text] [Related]
12. Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective.
Ross C; Marshman G; Grillo M; Stanford T
Australas J Dermatol; 2016 May; 57(2):137-40. PubMed ID: 25754697
[TBL] [Abstract][Full Text] [Related]
13. Efficacy comparison of ustekinumab between anti-tumor necrosis factor-α drug-naïve and anti-tumor necrosis factor-α drug-resistant Japanese psoriasis cases.
Takahashi N; Noda S; Taniguchi T; Adachi M
Int J Dermatol; 2015 Oct; 54(10):1194-8. PubMed ID: 26016819
[TBL] [Abstract][Full Text] [Related]
14. Biologic Therapies in HIV-infected Patients with Psoriasis: An Italian Experience.
Bardazzi F; Magnano M; Campanati A; Loconsole F; Carpentieri A; Potenza C; Bernardini N; Di Lernia V; Carrera C; Raone B; Patrizi A; Loi C
Acta Derm Venereol; 2017 Aug; 97(8):989-990. PubMed ID: 28512671
[No Abstract] [Full Text] [Related]
15. Paradoxical Reactions: Anti-Tumor Necrosis Factor Alpha Agents, Ustekinumab, Secukinumab, Ixekizumab, and Others.
Puig L
Curr Probl Dermatol; 2018; 53():49-63. PubMed ID: 29131037
[TBL] [Abstract][Full Text] [Related]
16. Prolongation of Biologic Dosing Intervals in Patients With Stable Psoriasis: A Feasibility Study.
van Bezooijen JS; van Doorn MBA; Schreurs MWJ; Koch BCP; Te Velthuis H; Prens EP; van Gelder T
Ther Drug Monit; 2017 Aug; 39(4):379-386. PubMed ID: 28570371
[TBL] [Abstract][Full Text] [Related]
17. 'Happy' drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network.
van den Reek JM; Zweegers J; Kievit W; Otero ME; van Lümig PP; Driessen RJ; Ossenkoppele PM; Njoo MD; Mommers JM; Koetsier MI; Arnold WP; Sybrandy-Fleuren BA; Kuijpers AL; Andriessen MP; van de Kerkhof PC; Seyger MM; de Jong EM
Br J Dermatol; 2014 Nov; 171(5):1189-96. PubMed ID: 24807471
[TBL] [Abstract][Full Text] [Related]
18. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review.
Garber C; Creighton-Smith M; Sorensen EP; Dumont N; Gottlieb AB
J Drugs Dermatol; 2015 Aug; 14(8):881-6. PubMed ID: 26267734
[TBL] [Abstract][Full Text] [Related]
19. Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation.
Whitlock SM; Enos CW; Armstrong AW; Gottlieb A; Langley RG; Lebwohl M; Merola JF; Ryan C; Siegel MP; Weinberg JM; Wu JJ; Van Voorhees AS
J Am Acad Dermatol; 2018 Feb; 78(2):383-394. PubMed ID: 29332708
[TBL] [Abstract][Full Text] [Related]
20. Adalimumab administration after infliximab therapy is a successful treatment strategy for generalized pustular psoriasis.
Matsumoto A; Komine M; Karakawa M; Kishimoto M; Ohtsuki M
J Dermatol; 2017 Feb; 44(2):202-204. PubMed ID: 27743397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
